Related Experiment Video
Updated: Oct 27, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable
Veena Kochat1,2, Ayush T Raman2,3,4, Sharon M Landers1
1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that frequently harbor genetic alterations in polycomb repressor complex 2 (PRC2) components-SUZ12 and EED. Here, we show that PRC2 loss confers a dedifferentiated early neural-crest phenotype which is exclusive to PRC2-mutant MPNSTs and not a feature of neurofibromas. Neural crest phenotype in PRC2 mutant MPNSTs was validated via cross-species comparative analysis using spontaneous and transgenic MPNST models. Systematic chromatin state profiling of the MPNST cells showed extensive epigenomic reprogramming or chromatin states associated with PRC2 loss and identified gains of active enhancer states/super-enhancers on early neural crest regulators in PRC2-mutant conditions around genomic loci that harbored repressed/poised states in PRC2-WT MPNST cells. Consistently, inverse correlation between H3K27me3 loss and H3K27Ac gain was noted in MPNSTs. Epigenetic editing experiments established functional roles for enhancer gains on DLX5-a key regulator of neural crest phenotype. Consistently, blockade of enhancer activity by bromodomain inhibitors specifically suppressed this neural crest phenotype and tumor burden in PRC2-mutant PDXs. Together, these findings reveal accumulation of dedifferentiated neural crest like state in PRC2-mutant MPNSTs that can be targeted by enhancer blockade.
Insights
Loss of Polycomb Repressor Complex 2 (PRC2) in malignant peripheral nerve sheath tumors (MPNSTs) drives a dedifferentiated neural crest state. This phenotype, targetable by enhancer blockade, distinguishes MPNSTs from neurofibromas.
Area of Science:
- Oncology
- Epigenetics
- Developmental Biology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas.
- Genetic alterations in Polycomb Repressor Complex 2 (PRC2) components (SUZ12, EED) are common in MPNSTs.
Purpose of the Study:
- To investigate the functional consequences of PRC2 loss in MPNSTs.
- To identify therapeutic targets associated with PRC2-mutant MPNSTs.
Main Methods:
- Comparative analysis of PRC2-mutant and PRC2-wild-type MPNSTs.
- Chromatin state profiling and epigenomic analysis.
- Cross-species comparative analysis using MPNST models.
- Functional validation using epigenetic editing and bromodomain inhibitors.
Main Results:
- PRC2 loss induces a dedifferentiated early neural crest phenotype specific to MPNSTs.
- Epigenomic reprogramming involves gains of active enhancers on neural crest regulators in PRC2-mutant MPNSTs.
- Enhancer activity, particularly on DLX5, is functionally critical for the neural crest phenotype.
- Bromodomain inhibitors targeting enhancer activity suppressed tumor growth in PRC2-mutant models.
Conclusions:
- PRC2-mutant MPNSTs accumulate a dedifferentiated neural crest-like state.
- Targeting enhancer activity represents a potential therapeutic strategy for PRC2-mutant MPNSTs.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
Abnormal Proliferation
Somatic to iPS Cell Reprogramming
Introduction to Nuclear Reprogramming